Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Colorcon
Federal Trade Commission
UBS
Boehringer Ingelheim
US Department of Justice
Daiichi Sankyo
Johnson and Johnson
Chinese Patent Office
Novartis

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 071620

« Back to Dashboard
NDA 071620 describes TEMAZEPAM, which is a drug marketed by Duramed Pharms Barr, Actavis Elizabeth, Mylan, Sandoz, Watson Labs, Novel Labs Inc, Sun Pharm Inds, Prinston Inc, Amneal Pharms, and Usl Pharma, and is included in nineteen NDAs. It is available from thirty-nine suppliers. Additional details are available on the TEMAZEPAM profile page.

The generic ingredient in TEMAZEPAM is temazepam. There are seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the temazepam profile page.

Summary for NDA: 071620

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 071620

Ingredient-typeBenzodiazepines

Suppliers and Packaging for NDA: 071620

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TEMAZEPAM
temazepam
CAPSULE;ORAL 071620 ANDA Actavis Pharma, Inc. 0228-2076 0228-2076-10 100 CAPSULE in 1 BOTTLE (0228-2076-10)
TEMAZEPAM
temazepam
CAPSULE;ORAL 071620 ANDA Actavis Pharma, Inc. 0228-2076 0228-2076-50 500 CAPSULE in 1 BOTTLE (0228-2076-50)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength30MG
Approval Date:Aug 7, 1987TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength15MG
Approval Date:Aug 7, 1987TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Citi
Chinese Patent Office
Fuji
Merck
US Department of Justice
McKinsey
Novartis
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot